Physician profile
Susan E Webb
NPI 1518935311
$6,617.42
in general payments reported to CMS, 2019-2025
39 companies · $198 in 2025
The $198 reported for 2025 was more than what a typical Gynecology provider received nationally (typical 2025 total: $162).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,772 · 2020: $1,171 · 2021: $1,498 · 2022: $1,039 · 2023: $804 · 2024: $135 · 2025: $198.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,137.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,137.23 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Pfizer INC. | $952.45 | 2019-2024 | |
| Novo Nordisk INC | $947.49 | 2019-2025 | Wegovy, Saxenda |
| Allergan, INC. | $566.96 | 2019-2021 | |
| Therapeuticsmd, INC. | $499.45 | 2019-2022 | |
| Abbvie INC. | $445.61 | 2019-2024 | Liletta, Vraylar |
| Aspira Women'S Health INC | $342.67 | 2022-2023 | Ova1 |
| Daiichi Sankyo INC. | $327.40 | 2019-2021 | |
| Lupin INC. | $325.75 | 2019-2021 | |
| Avion Pharmaceuticals | $252.56 | 2019-2023 | Balcoltra |
| Mayne Pharma Commercial LLC | $226.40 | 2021-2025 | |
| Biohaven Pharmaceuticals, INC. | $215.35 | 2020-2021 | |
| Astellas Pharma US INC | $204.75 | 2021-2025 | Veozah |
| Amag Pharmaceuticals, INC. | $198.35 | 2019 | |
| Myovant Sciences INC. | $137.50 | 2021-2022 | |
| Exeltis, USA INC. | $131.08 | 2020-2024 | Slynd |
Show all 39 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Susan Webb listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.